Table 1.
Anthropometric data of included volunteers and MDMA doses according to gender and genotypes (mean ± SD [min, max]).
Table 2.
MDMA doses (total oral and weight-adjusted) and genetic polymorphism of CYP2D6, COMT, and 5-HTTLPR in women and men.
Table 3.
Gender differences in pharmacokinetic parameters of MDMA and its metabolites (mean ± SD; for MDMA and HMMA: women n = 11 vs. men n = 15; for MDA and HMA: women n = 11 vs. men n = 12).
Table 4.
Gender differences in physiological and subjective effects after MDMA administration (mean ± SD; women n = 12 vs. men n = 15) (only significant effects included).
Table 5.
Genetic differences in physiological and subjective effects after MDMA administration (mean ± SD; women n = 12 vs. men n = 15) (only significant effects included).
Figure 1.
Plasma Concentrations of MDMA, HMMA, MDA, and HMA in both genders (mean ± standard error of the mean, SEM; for MDMA and HMMA: women n = 11 vs. men n = 15; for MDA and HMA: women n = 11 vs. men n = 12).
Influence of CYP2D6 genotype in plasma concentrations of HMMA (mean ± SEM; subjects with 2 FA n = 18 vs. with 1 FA n = 8. *p<0.05, **p<0.01.
Figure 2.
Influence of gender and genetics (COMT, 5-HTTLPR) on the temporal course of systolic blood pressure (upper-left panel), heart rate (lower-left panel), and oral temperature (right-end panel) (mean ± SEM); women n = 12 vs. men n = 15; COMT, val/val n = 8 vs. met/* n = 18; 5-HTTLPR, l/* n = 18 vs. s/s n = 9).
*p<0.05, **p<0.01. Graph A corresponds to gender differences in OT, graph B corresponds to differences in OT as a function of 5-HTTLPR polymorphisms (l/l n = 11 vs. s/s n = 9). Subjects l/s (n = 7) are not represented for graph clarity, but data almost fully overlaps with the s/s trace.